PA8481901A1 - Administracion de agente activo en polvo seco - Google Patents

Administracion de agente activo en polvo seco

Info

Publication number
PA8481901A1
PA8481901A1 PA19998481901A PA8481901A PA8481901A1 PA 8481901 A1 PA8481901 A1 PA 8481901A1 PA 19998481901 A PA19998481901 A PA 19998481901A PA 8481901 A PA8481901 A PA 8481901A PA 8481901 A1 PA8481901 A1 PA 8481901A1
Authority
PA
Panama
Prior art keywords
active agent
administration
dry powder
inhibitor
hygroscopic growth
Prior art date
Application number
PA19998481901A
Other languages
English (en)
Spanish (es)
Inventor
Barry John Aldous
Andrew Clark
Kuo Mei Chang
Cecily Lalor
Original Assignee
Inhale Therapeutic Syst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhale Therapeutic Syst filed Critical Inhale Therapeutic Syst
Publication of PA8481901A1 publication Critical patent/PA8481901A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
PA19998481901A 1998-09-14 1999-09-14 Administracion de agente activo en polvo seco PA8481901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10016398P 1998-09-14 1998-09-14

Publications (1)

Publication Number Publication Date
PA8481901A1 true PA8481901A1 (es) 2002-04-25

Family

ID=22278404

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19998481901A PA8481901A1 (es) 1998-09-14 1999-09-14 Administracion de agente activo en polvo seco

Country Status (44)

Country Link
EP (1) EP1117442A1 (hu)
JP (1) JP2002524535A (hu)
KR (1) KR20010075063A (hu)
CN (1) CN1317977A (hu)
AP (1) AP1374A (hu)
AR (1) AR022090A1 (hu)
AU (1) AU753014B2 (hu)
BG (1) BG105430A (hu)
BR (1) BR9913722A (hu)
CA (1) CA2343920A1 (hu)
CO (1) CO5130023A1 (hu)
CZ (1) CZ2001829A3 (hu)
DZ (1) DZ2892A1 (hu)
EA (1) EA003476B1 (hu)
EE (1) EE200100151A (hu)
GE (1) GEP20043257B (hu)
GT (1) GT199900156A (hu)
HK (1) HK1042231A1 (hu)
HN (1) HN1999000159A (hu)
HR (1) HRP20010189A2 (hu)
HU (1) HUP0103837A3 (hu)
ID (1) ID28845A (hu)
IL (2) IL141562A0 (hu)
IS (1) IS5878A (hu)
LT (1) LT4897B (hu)
LV (1) LV12658B (hu)
MA (1) MA25590A1 (hu)
MY (1) MY129282A (hu)
NO (1) NO20011251L (hu)
NZ (1) NZ510168A (hu)
OA (1) OA11781A (hu)
PA (1) PA8481901A1 (hu)
PE (1) PE20001061A1 (hu)
PL (1) PL195574B1 (hu)
SA (1) SA99200718B1 (hu)
SK (1) SK3442001A3 (hu)
TN (1) TNSN99173A1 (hu)
TR (1) TR200101182T2 (hu)
TW (1) TWI226248B (hu)
UA (1) UA76085C2 (hu)
UY (1) UY25711A1 (hu)
WO (1) WO2000015262A1 (hu)
YU (1) YU24201A (hu)
ZA (1) ZA200101995B (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075281A2 (en) 1999-06-09 2000-12-14 University Technology Corporation Supercritical fluid-assisted nebulization and bubble drying
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
JP2005518453A (ja) 2002-02-25 2005-06-23 ディフュージョン・ファーマシューティカルズ・エルエルシー 二極性トランスカロテノイド塩およびそれらの使用
EP1539246A4 (en) * 2002-07-03 2007-05-16 Brigham & Womens Hospital ADMINISTRATION IN THE CENTRAL AIRWAYS FOR THE SYSTEMIC DELIVERY OF THERAPEUTICS
BR0317392A (pt) * 2002-12-19 2005-12-20 Pharmacia Corp Formulação não-higroscópica incluindo uma droga higroscópica
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
MXPA06012240A (es) * 2004-04-23 2007-01-31 Cydex Inc Formulacion para inhalador de polvo seco que contiene eter sulfoalquilico-ciclodextrina.
NZ561664A (en) 2005-02-24 2011-02-25 Diffusion Pharmaceuticals Llc Trans carotenoids, their synthesis, formulation and uses
EP1857114A1 (en) * 2005-03-09 2007-11-21 Ono Pharmaceutical Co., Ltd. Particle and preparation containing the particle
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
PT2583668E (pt) 2005-10-26 2015-01-05 Cydex Pharmaceuticals Inc Composições de éter sulfoalquílico de ciclodextrina e métodos para a sua preparação
US20080035143A1 (en) * 2006-08-14 2008-02-14 Sievers Robert E Human-powered dry powder inhaler and dry powder inhaler compositions
CN101541311B (zh) * 2006-10-25 2013-01-23 大日本住友制药株式会社 不易结块的颗粒制剂
EP1925295A1 (de) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stabile Pulverformulierung enthaltend ein Anticholinergikum
CN101687757A (zh) 2007-04-13 2010-03-31 扩散药品有限公司 双极性反式类胡萝卜素作为预治疗及其在周围血管疾病的治疗中的应用
BRPI0818119A2 (pt) 2007-10-31 2015-08-04 Diffusion Pharmaceuticals Llc Uma nova classe de produtos terapêuticos que melhoram difusão de molécula pequena
ES2661215T3 (es) 2009-05-20 2018-03-28 Aeras Composiciones víricas; inmunógenas; secadas por pulverización; estables
EP3539542B1 (en) 2009-06-22 2023-04-19 Diffusion Pharmaceuticals LLC Diffusion enhancing compounds and their use with a thrombolytic
AU2011262361A1 (en) 2010-06-02 2013-01-10 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
BR112014026957A8 (pt) * 2012-05-03 2018-01-16 Janssen R&D Ireland micropartícula, composição compreendendo a mesma, seu uso e sistema de distribuição nasal relacionados ao tratamento de infecções do trato respiratório superior
BR112015010601B1 (pt) * 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
WO2015042352A1 (en) * 2013-09-20 2015-03-26 Virginia Commonwealth University Delivery of particles using hygroscopic excipients
AU2015338717B2 (en) 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation
JP7032320B2 (ja) 2016-03-24 2022-03-08 ディフュージョン・ファーマシューティカルズ・エルエルシー 癌を処置するための、化学療法及び放射線療法を伴う二極性トランスカロテノイドの使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155573A (en) * 1958-05-06 1964-11-03 Benger Lab Ltd Inhalant composition and method of making same
ATE222754T1 (de) * 1992-06-12 2002-09-15 Teijin Ltd Ultrafeines pulver zur inhalation und dessen herstellung
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
ATE287257T1 (de) * 1997-01-16 2005-02-15 Massachusetts Inst Technology Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant

Also Published As

Publication number Publication date
AU753014B2 (en) 2002-10-03
KR20010075063A (ko) 2001-08-09
BR9913722A (pt) 2001-05-29
NO20011251L (no) 2001-04-17
HRP20010189A2 (en) 2005-04-30
PL346768A1 (en) 2002-02-25
GT199900156A (es) 2001-03-07
AR022090A1 (es) 2002-09-04
CO5130023A1 (es) 2002-02-27
LT2001021A (en) 2001-11-26
OA11781A (en) 2005-07-26
DZ2892A1 (fr) 2003-12-15
EP1117442A1 (en) 2001-07-25
HUP0103837A3 (en) 2002-11-28
WO2000015262A1 (en) 2000-03-23
HK1042231A1 (zh) 2002-08-09
MA25590A1 (fr) 2002-12-31
EA003476B1 (ru) 2003-06-26
NO20011251D0 (no) 2001-03-13
LV12658A (lv) 2001-05-20
CZ2001829A3 (cs) 2001-09-12
YU24201A (sh) 2003-08-29
TNSN99173A1 (fr) 2005-11-10
JP2002524535A (ja) 2002-08-06
TWI226248B (en) 2005-01-11
ZA200101995B (en) 2002-03-11
NZ510168A (en) 2003-09-26
IL141562A0 (en) 2002-03-10
IL141562A (en) 2007-07-24
BG105430A (en) 2001-12-29
SK3442001A3 (en) 2001-11-06
ID28845A (id) 2001-07-05
AP2001002093A0 (en) 2001-03-31
UA76085C2 (en) 2006-07-17
PL195574B1 (pl) 2007-10-31
LT4897B (lt) 2002-02-25
EE200100151A (et) 2002-06-17
HUP0103837A2 (hu) 2002-05-29
SA99200718B1 (ar) 2006-11-04
LV12658B (lv) 2001-09-20
CA2343920A1 (en) 2000-03-23
AU6039799A (en) 2000-04-03
MY129282A (en) 2007-03-30
AP1374A (en) 2005-02-28
GEP20043257B (en) 2004-06-25
UY25711A1 (es) 1999-11-17
CN1317977A (zh) 2001-10-17
EA200100300A1 (ru) 2001-10-22
TR200101182T2 (tr) 2001-09-21
HN1999000159A (es) 1999-11-11
IS5878A (is) 2001-03-05
PE20001061A1 (es) 2000-10-08

Similar Documents

Publication Publication Date Title
PA8481901A1 (es) Administracion de agente activo en polvo seco
AR020760A1 (es) DISPOSITIVO PARA CONTROLAR LA ADMINISTRACIoN DE UN AGENTE ACTIVO EN AEROSOL EN LOS PULMONES DE UN PACIENTE HUMANO
CO5060522A1 (es) Administracion de un agente activo en aerosol
ES2159591T3 (es) Composicion de liberacion controlada.
ES2073205T3 (es) Agentes con efecto refrigerante fisiologico y compuestos activos apropiados para estos agentes.
AR002754A1 (es) Composición farmacéutica que comprende bacterias lactobacillus viables micro-encapsuladas, y uso de la composición para preparar de un medicamento
DE60027463D1 (de) Pharmazeutische zusammensetzungen enthaltend resveratrol und verwendungen davon
ES2117015T3 (es) Composiciones que contienen sumatriptan.
DE3382458D1 (de) Haarwuchsmittel.
ES2064121T3 (es) Agente para reducir o eliminar el crecimiento de los pelos del cuerpo humano.
MX9300620A (es) Formulacion farmaceutica en aerosol e inhalador para la administracion de dipropionato de beclometasona.
ES2185817T3 (es) Formas de dosificacion farmaceutica oral que comprenden un inhibidor de las bombas de protones y un agente antiacido o alginato.
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
UY25544A1 (es) Forma de dosificación de nefazodona
BR0311460A (pt) Composição farmacêutica de liberação modificada, uso de uma formulação, e, método para tratar um distúrbio cardiovascular em um paciente
NO951498L (no) Farmasöytisk preparat for behandling av osteoporose
ES2184145T3 (es) Compuestos de acido sulfonico o sulfonilamino-n-(heteroaralquil)-azaheterociclilamida.
AR024998A1 (es) Nuevos retinoides para el tratamiento del enfisema
CN111214689A (zh) 一种高效预防新型冠状病毒肺炎和流感的香囊
NO994431L (no) Ny formulering
CO5580741A2 (es) Composicion farmaceutica que comprende un agonista de receptor de 5ht1
AR021086A1 (es) Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento.
ES2179960T3 (es) Solucion de conservacion para organos o tejidos, o partes de los mismos, de seres humanos o animales.
AR026254A1 (es) El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4
BR9917389A (pt) Formulações tópicas compreendendo agentes de penetração na pele e o uso das mesmas